Caplin Point Laboratories share news, announcements and annual reports
NSE: CAPLIPOINTBSE: 524742Pharmaceuticals & BiotechnologySmall Cap
Caplin Point Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1995 on BSE, Jun 2014 on NSE
Last close ₹2,325.60down ₹50.50 (2.13%)BSE ₹2,324.85
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,376.10.
30 Oct: open ₹2,377.40, high ₹2,422.40, low ₹2,310.00
52-week range of traded prices to 30 Oct 2026
₹1,500.30Low, 30 Mar 2026₹2,990.00High, 24 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹17,677 Cr453rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.57
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.93
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.34%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,28,33948.3% delivered
Caplin Point Laboratories share news and announcements
492 announcements, routine notices left out, newest first. Page 8 of 10.
Nov 2018
30 Nov · Updates
19 Nov · Board meeting
12 Nov · Board meeting
2 Nov · Results
Oct 2018
Sep 2018
30 Sep · Updates
29 Sep · Updates
4 Sep · Updates
Aug 2018
6 Aug · Results
Jul 2018
12 Jul · Board meeting
Jun 2018
6 Jun · Business
1 Jun · Updates
May 2018
28 May · Results
8 May · Management
Apr 2018
Mar 2018
12 Mar · Board meeting
1 Mar · Board meeting
Feb 2018
15 Feb · Disclosure
7 Feb · Management
7 Feb · Disclosure
7 Feb · Results
Jan 2018
Nov 2017
9 Nov · Board meeting
9 Nov · Results
Oct 2017
Sep 2017
22 Sep · Meeting
Aug 2017
8 Aug · Legal
Exchange has sought clarification from Caplin Point Laboratories Limited with respect to announcement dated 07-Aug-2017, regarding "Outcome of Board Meeting held on August 07, 2017."On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);2. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.7 Aug · Board meeting
7 Aug · Results
Jul 2017
May 2017
17 May · Results
10 May · Results